PL2504451T3 - Sposoby przewidywania wyników klinicznych dla nowotworu - Google Patents

Sposoby przewidywania wyników klinicznych dla nowotworu

Info

Publication number
PL2504451T3
PL2504451T3 PL10832289T PL10832289T PL2504451T3 PL 2504451 T3 PL2504451 T3 PL 2504451T3 PL 10832289 T PL10832289 T PL 10832289T PL 10832289 T PL10832289 T PL 10832289T PL 2504451 T3 PL2504451 T3 PL 2504451T3
Authority
PL
Poland
Prior art keywords
cancer
methods
clinical outcome
predict clinical
predict
Prior art date
Application number
PL10832289T
Other languages
English (en)
Polish (pl)
Inventor
Joffre B. Baker
Maureen T. Cronin
Francois Collin
Mei-lan LIU
Original Assignee
Genomic Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health, Inc. filed Critical Genomic Health, Inc.
Publication of PL2504451T3 publication Critical patent/PL2504451T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10832289T 2009-11-23 2010-11-19 Sposoby przewidywania wyników klinicznych dla nowotworu PL2504451T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer
EP10832289.2A EP2504451B1 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (1)

Publication Number Publication Date
PL2504451T3 true PL2504451T3 (pl) 2019-09-30

Family

ID=44060376

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10832289T PL2504451T3 (pl) 2009-11-23 2010-11-19 Sposoby przewidywania wyników klinicznych dla nowotworu

Country Status (13)

Country Link
US (4) US20110123990A1 (enExample)
EP (4) EP4350001A3 (enExample)
JP (7) JP5964752B2 (enExample)
AU (1) AU2010321829B2 (enExample)
CA (2) CA2776751C (enExample)
DK (1) DK2504451T3 (enExample)
ES (1) ES2735993T3 (enExample)
HU (1) HUE044374T2 (enExample)
IL (5) IL219051A (enExample)
MX (3) MX391499B (enExample)
NZ (1) NZ599194A (enExample)
PL (1) PL2504451T3 (enExample)
WO (1) WO2011063274A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
RU2011102743A (ru) * 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
CA3256492A1 (en) 2010-01-11 2025-11-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
WO2012135008A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US10559048B2 (en) * 2011-07-13 2020-02-11 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
CA2844805A1 (en) * 2011-08-16 2013-02-21 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
EP2776830B1 (en) * 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
SG11201404390WA (en) 2012-01-31 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
CA2871076A1 (en) * 2012-04-20 2013-10-24 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
US20150299799A1 (en) 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
ES2829415T3 (es) * 2013-05-30 2021-05-31 Genomic Health Inc Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
FI3198035T3 (fi) 2014-09-26 2023-01-31 Menetelmiä lääkevasteen ennustamiseksi
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
CN108350485A (zh) 2015-10-30 2018-07-31 精密科学发展有限责任公司 血浆dna的多重扩增检测测定以及分离和检测
US11401558B2 (en) 2015-12-18 2022-08-02 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CN110225984A (zh) * 2016-09-07 2019-09-10 科技研究局 鉴别癌症风险的方法和治疗选择
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN110475875B (zh) 2017-01-27 2024-06-25 精密科学公司 通过分析甲基化dna检测结肠瘤形成
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
MX389484B (es) 2017-11-13 2025-03-20 The Multiple Myeloma Res Foundation Inc Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
WO2019173647A1 (en) * 2018-03-08 2019-09-12 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and adminstering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
JP7444376B2 (ja) * 2018-09-21 2024-03-06 国立大学法人 東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
US20220033912A1 (en) * 2018-12-08 2022-02-03 Pfs Genomics Inc Transcriptomic profiling for prognosis of breast cancer to identify subjects who may be spared adjuvant systemic therapy
CN113785076B (zh) * 2019-05-03 2024-06-11 株式会社递希真 预测癌症预后的方法及其组合物
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2022174089A1 (en) * 2021-02-12 2022-08-18 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
US20220285032A1 (en) * 2021-03-08 2022-09-08 Castle Biosciences, Inc. Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
WO2006037485A2 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
JP2008534002A (ja) * 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
JP2010524456A (ja) * 2007-04-16 2010-07-22 イプソゲン 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
EP2641978A1 (en) * 2008-05-12 2013-09-25 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
CA3043089A1 (en) 2011-05-26
JP2022166064A (ja) 2022-11-01
IL276487B (en) 2022-03-01
IL276487A (en) 2020-09-30
JP2024037948A (ja) 2024-03-19
MX363817B (es) 2019-04-04
EP3739060A1 (en) 2020-11-18
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
US20210062275A1 (en) 2021-03-04
JP2021058207A (ja) 2021-04-15
EP2504451A4 (en) 2016-07-06
EP4350001A3 (en) 2024-06-19
WO2011063274A3 (en) 2014-03-27
JP7042717B2 (ja) 2022-03-28
CA2776751C (en) 2019-07-02
MX337650B (es) 2016-03-14
AU2010321829A1 (en) 2012-05-03
IL249159A0 (en) 2017-01-31
EP2504451B1 (en) 2019-06-05
IL264072A (en) 2019-02-28
JP2016214245A (ja) 2016-12-22
CA2776751A1 (en) 2011-05-26
NZ599194A (en) 2014-07-25
MX391499B (es) 2025-03-21
US20110123990A1 (en) 2011-05-26
AU2010321829B2 (en) 2015-07-30
IL264072B (en) 2020-08-31
MX2012005822A (es) 2012-06-19
MX2019003811A (es) 2019-08-05
EP2504451A2 (en) 2012-10-03
EP3556867A1 (en) 2019-10-23
WO2011063274A2 (en) 2011-05-26
IL219051A (en) 2016-12-29
JP5964752B2 (ja) 2016-08-03
JP2018196385A (ja) 2018-12-13
DK2504451T3 (da) 2019-08-05
IL219051A0 (en) 2012-06-28
JP2022169647A (ja) 2022-11-09
ES2735993T3 (es) 2019-12-23
JP2013514058A (ja) 2013-04-25
US20170211154A1 (en) 2017-07-27
EP4350001A2 (en) 2024-04-10
US20190241967A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
IL276487B (en) Methods for predicting clinical outcome of cancer
IL276362A (en) Cancer treatment methods
IL256335B (en) A method for using gene expression to determine the likelihood of clinical outcome in kidney cancer
IL229114B (en) Methods for predicting response to cancer treatment using servalon as a predictor
IL218575A0 (en) Treatment of cancer
ZA201206019B (en) Methods for predicting response of triple-negative breast cancer to therapy
PL2297359T4 (pl) Profile ekspresji genów do przewidywania skutków raka piersi
EP2438197A4 (en) METHOD OF CANCER DETECTION
ZA201208821B (en) Methods of treatment of pancreatic cancer
PL2435825T3 (pl) Sposoby leczenia chorób
EP2461814A4 (en) PROSTATE CANCER TREATMENT
ZA201304226B (en) Methods of treating cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
EP2501845A4 (en) KREBSBIOMARKER
EP2593100A4 (en) METHOD OF TREATING REFRACTORY CANCER
IL213919A0 (en) Methods to treat cancer
GB0916686D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
IL223237A0 (en) Diagnosis of cancer
GB201017354D0 (en) Treatment of cancer
GB201007977D0 (en) Treatment of cardiovascular disease
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer
GB0908666D0 (en) Treatment of proteostatic disease